| Literature DB >> 24885209 |
Hillary F Berman, Sara Yee Tartof, Joice N Reis, Mitermayer G Reis, Lee W Riley1.
Abstract
BACKGROUND: Group A streptococcus (GAS) causes invasive disease, superficial disease, and can asymptomatically colonize humans. Superantigens are one virulence factor found in GAS. Previous studies found associations between the genes that encode superantigens and emm type of GAS. It is unknown if these associations are due to underlying biological factors that limit the distribution of superantigens or, alternatively, if these associations are due to the expansion of local GAS linages where these studies took place. To further address this question we screened GAS isolates collected from Salvador, Brazil for 11 known superantigen genes.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24885209 PMCID: PMC4045995 DOI: 10.1186/1471-2334-14-294
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Primers used
| 5′-GGACTAACAATCTCGCAAGAGG-3′ | 5′-TTACTTGGTTGTTAGGTAGACTTC-3′ | 54 | 696 | |
| 5′-GCTAACAACCTCACAAGAAG -3′ | 5′-TGCTTGAGTCAAGCGTCTC-3′ | 53 | 659 | |
| 5′-GATTTCTACTATTTCACC-3′ | 5′-AAATATCTGATCTAGTCCC-3′ | 44 | 584 | |
| 5′-CTTATGCAGATGAAAATTTAAAAGATT-3′ | 5′-AAAGCAAAGGGGGGAGAATAG-3′ | 53.2 | 664 | |
| 5′-ATGAGTAGTGTGGGAGTTATTAA-3′ | 5′-ATGAAGTTGATCAGAATAAGCG-3′ | 55 | 645 | |
| 5′-ATCTTATTTAGTCCAAAGGTAAAT-3′ | 5′-GTGAACGAGGAGAGGTATGAA-3′ | 55.5 | 718 | |
| 5′-TTGGATTAGAAGTAGATAA-3′ | 5′-TTGAATTAGGAGTCAATTTCTATATCT-3′ | 52 | 638 | |
| 5′-AGTCAGCCTGACCCTACTCCA-3′ | 5′-TAAGGTGAACCTCTATAGCTATAG-3′ | 59.1 | 691 | |
| 5′-TTGGATCCAATTCTTATAATACAACC-3′ | 5′-CCACTTCCTGAGCGGTTACTTTCGG-3′ | 50 | 399 | |
| 5′-CTATGGTGGAATTACACC-3′ | 5′-CATGTTTATTGCCATTGATCGC-3′ | 50 | 247 | |
| 5′-GCGGATCCGATACGTACAATACAAATG-3′ | 5′-GCGAATTCAATAGCATTCAACCA-3′ | 50 | 798 | |
| 5′-GCAGCCATATGGAAGAGACTATTCCTCTTAAGGATATATACTCTC-3′ | 5′-GGGGATCCTTAATTTTCTTTGTTTGTGAATAAATAGAC-3′ | 50 | 703 | |
| 5′-GCAGCCATATGTTTTCAGATGCTGTGTTGG-3′ | 5′-GGGGATCCTTAATTTTTAGAAAAATCTTCGTTTAAGTA-3′ | 50 | 661 | |
| 5′-GGATCCCAACCAGTTGTTAAATCTCT-3′ | 5′-AACGTTCTAAGGTTTGATGCCTACAA-3′ | 50 | 774 |
All primer sequences shown here have previously been published by Maripuu et al. or Commons et al.
Distribution of superantigens by type
| 32 (42%) | 25 (100%) | 1 (3%) | 6 (50%) | p < .001 | |
| 33 (43%) | 0 | 33 (83%) | 0 | p < .001 | |
| 77 (100%) | 25 (100%) | 40 (100%) | 12 (100%) | | |
| 28 (36%) | 0 | 22 (55%) | 6 (50%) | p < .001 | |
| 48 (62%) | 4 (16%) | 37 (93%) | 7 (58%) | p < .001 | |
| 11 (14%) | 9 (36%) | 1 (3%) | 1 (8%) | p < .001 | |
| 0 | 0 | 0 | 0 | | |
| 0 | 0 | 0 | 0 | | |
| 4 (5%) | 1 (4%) | 3 (8%) | 0 | | |
| 6 (8%) | 1 (4%) | 4 (10%) | 1 (8%) | | |
| 76 (99%) | 25 (100%) | 40 (100%) | 11 (92%) |
Superantigen genotype and distribution across type
| A (n = 1) | X | | X | | X | | | | X | | X | 0 | 1 (4%) | 0 | |
| B (n = 17) | X | | X | | | | | | | | X | 0 | 13 (52%) | 4 (33.3%) | <.001 |
| C (n = 1) | X | | X | | | X | | | | X | X | 0 | 1 (4%) | 0 | |
| D (n = 7) | X | | X | | | X | | | | | X | 0 | 7 (28%) | 0 | <.001 |
| E (n = 3) | X | | X | | X | | | | | | X | 0 | 2 (8%) | 1 (8.3%) | |
| F (n = 1) | X | | X | | X | X | | | | | X | 0 | 1 (4%) | 0 | |
| G (n = 1) | | | X | X | X | | | | X | | X | 1 (2.5%) | 0 | 0 | |
| H (n = 2) | | X | X | X | X | | | | | X | X | 2 (5%) | 0 | 0 | |
| J (n = 19) | | X | X | X | X | | | | | | X | 19 (47.5%) | 0 | 0 | <.001 |
| K (n = 3) | | X | X | | | | | | | | X | 3 (7.5%) | 0 | 0 | |
| M (n = 2) | | X | X | X | X | | | | X | | X | 2 (5%) | 0 | 0 | |
| N (n = 8) | | | X | X | X | | | | | | X | 5 (12.5%) | 0 | 3 (25%) | |
| O (n = 1) | X | X | X | X | X | | | | | | X | 1 (2.5%) | 0 | 0 | |
| P (n = 1) | | | X | | | | | | | | X | 0 | 0 | 1 (8.3%) | |
| Q (n = 4) | | X | X | | X | | | | | | X | 4 (10%) | 0 | 0 | |
| R (n = 1) | | X | X | X | X | X | | | | | X | 1 (2.5%) | 0 | 0 | |
| S (n = 1) | | X | X | | X | | | | | X | X | 1 (2.5%) | 0 | 0 | |
| T (n = 1) | | | X | X | X | X | | | | | | 0 | 0 | 1 (8.3%) | |
| U (n = 2) | | | X | X | X | | | | | X | X | 1 (2.5%) | 0 | 1 (8.3%) | |
| V (n = 1) | X | X | X | X | X | 0 | 0 | 1 (8.3%) |
Superantigen genotypes B and D were found significantly more often in emm type 1 isolates. Superantigen genotype J was found significantly more often in emm type 12 isolates. P-values were generated with the two-sided Fisher’s exact test.
Previously reported superantigen genotypes
| A (n = 1) | X | | X | | X | | | | X | | X | None | | | |
| B (n = 17) | X | | X | | | | | | | | X | R | Australia | 1 | 2001-2002
[ |
| | | | | | | | | | | | | A | Sweden | 1 | 1989
[ |
| C (n = 1) | X | | X | | | X | | | | X | X | F | Australia | 1 | 2001-2001
[ |
| D (n = 7) | X | | X | | | X | | | | | X | D | Australia | 1 | 2001-2002
[ |
| | | | | | | | | | | | | C | Sweden | 1 | 1988-2001
[ |
| | | | | | | | | | | | | Not Given | Norway | 1 | 2006-2007
[ |
| | | | | | | | | | | | | Not Given | New Zealand | 1 | Not given
[ |
| | | | | | | | | | | | | Not Given | Spain | 1 | 1999-2003
[ |
| | | | | | | | | | | | | I | Norway | 1 | 1988-2003
[ |
| | | | | | | | | | | | | Not Given | Sweden | 1 | 2006-2007
[ |
| E (n = 3) | X | | X | | X | | | | | | X | None | | | |
| F (n = 1) | X | | X | | X | X | | | | | X | None | | | |
| G (n = 1) | | | X | X | X | | | | X | | X | None | | | |
| H (n = 2) | | X | X | X | X | | | | | X | X | D | China | 1 | 2005-2006
[ |
| | | | | | | | | | | | | D | China | 12 | 1993-1994, 2005-2006
[ |
| J (n = 19) | | X | X | X | X | | | | | | X | H | Australia | 12 | 2001-2002
[ |
| | | | | | | | | | | | | S3 | Sweden | 12 | 1989-1993
[ |
| | | | | | | | | | | | | Not Given | Norway | 12 | 2006-2007
[ |
| | | | | | | | | | | | | Not Given | Spain | 12 | 1999-2003
[ |
| | | | | | | | | | | | | VII | Norway | 12 | 1988-2003
[ |
| | | | | | | | | | | | | S26 | Sweden | 66 | 1989
[ |
| K (n = 3) | | X | X | | | | | | | | X | None | | | |
| M (n = 2) | | X | X | X | X | | | | X | | X | None | | | |
| N (n = 8) | | | X | X | X | | | | | | X | J | Australia | 12 | 2001-2002
[ |
| | | | | | | | | | | | | Not Given | Norway | 12 | 2006-2007
[ |
| | | | | | | | | | | | | Not Given | Spain | 12 | 1999-2003
[ |
| | | | | | | | | | | | | AC | Sweden | 66 | 1988-1990
[ |
| O (n = 1) | X | X | X | X | X | | | | | | X | None | | | |
| P (n = 1) | | | X | | | | | | | | X | None | | | |
| Q (n = 4) | | X | X | | X | | | | | | X | None | | | |
| R (n = 1) | | X | X | X | X | X | | | | | X | Not Given | ATCC | 1 | Not given
[ |
| S (n = 1) | | X | X | | X | | | | | X | X | None | | | |
| T (n = 1) | | | X | X | X | X | | | | | | Not Given | New Zealand | 12 | Not given
[ |
| U (n = 2) | | | X | X | X | | | | | X | X | T | Australia | 12 | 2001-2002
[ |
| | | | | | | | | | | | | Not Given | Spain | 12 | 1999-2003
[ |
| V (n = 1) | X | X | X | X | X | None |
Previously published emm 1, 12 and 66 superantigen genotypes were reviewed and compared to our collection. “Genotype” refers to designations given in this paper. “Other name” refers to pattern name given in previously published work. Citations refer to the reference section.